Crossmark

Transarterial chemoembolization combined with tyrosine kinase inhibitors and programmed death-1 inhibitors in recurrent intermediate and advanced hepatocellular carcinoma: a single-centre retrospective cohort study

Crossref DOI link: https://doi.org/10.1186/s12876-026-05070-3

Published Online: 2026-07-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sui, Wei fan

Duan, Yu xin

Cai, Ze feng

Li, Jian yun

Fu, Jian hua
Funding

Funding for this research was provided by:

Jinshan Doctor Project (2025-JSYZ-33)
License Information

Text and Data Mining valid from 2026-07-09

Accepted Manuscript valid from 2026-07-09
More Information

Article History

Received: 8 April 2026

Accepted: 25 June 2026

First Online: 9 July 2026

Declarations

:

: The study protocol was approved by the institutional Ethics Committee of the Affiliated People’s Hospital of Jiangsu University (SQK-2025235-W) and consent to participate was waived by the Ethics Committee due to the retrospective nature of the study.

: Not Applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below